Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging. The company has a partnership and collaboration with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Sector

Healthcare

Industry

Biotechnology

CEO

Blou, Henrik

Employees

275

Website

www.gubra.dk

IPO Date

2023-04-04

Headquarters

Hørsholm Kongevej 11B, Horsholm, Capital Region of Denmark, 2970, Denmark

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Gubra GUBRA

Gubra Earnings Call Summary

Gubra Earnings

Transcripts

Events

About Gubra A/S

Gubra
GUBRA